Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study. Zepbound patients lost an average 20% of their body weight compared ...